284 related articles for article (PubMed ID: 12647987)
1. Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.
Tsimberidou AM; Alvarado Y; Giles FJ
Expert Rev Anticancer Ther; 2002 Aug; 2(4):437-48. PubMed ID: 12647987
[TBL] [Abstract][Full Text] [Related]
2. Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
Cory AH; Sato A; Thompson DP; Cory JG
Oncol Res; 1996; 8(10-11):449-56. PubMed ID: 9114437
[TBL] [Abstract][Full Text] [Related]
3. Ribonucleotide reductase inhibitors as anti-herpes agents.
Wnuk SF; Robins MJ
Antiviral Res; 2006 Sep; 71(2-3):122-6. PubMed ID: 16621038
[TBL] [Abstract][Full Text] [Related]
4. The enzyme ribonucleotide reductase: target for antitumor and anti-HIV therapy.
Szekeres T; Fritzer-Szekeres M; Elford HL
Crit Rev Clin Lab Sci; 1997; 34(6):503-28. PubMed ID: 9439883
[TBL] [Abstract][Full Text] [Related]
5. Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.
Finch RA; Liu M; Grill SP; Rose WC; Loomis R; Vasquez KM; Cheng Y; Sartorelli AC
Biochem Pharmacol; 2000 Apr; 59(8):983-91. PubMed ID: 10692563
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory mechanisms of heterocyclic carboxaldehyde thiosemicabazones for two forms of human ribonucleotide reductase.
Zhu L; Zhou B; Chen X; Jiang H; Shao J; Yen Y
Biochem Pharmacol; 2009 Nov; 78(9):1178-85. PubMed ID: 19576866
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies.
Gojo I; Tidwell ML; Greer J; Takebe N; Seiter K; Pochron MF; Johnson B; Sznol M; Karp JE
Leuk Res; 2007 Sep; 31(9):1165-73. PubMed ID: 17324462
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone).
Barker CA; Burgan WE; Carter DJ; Cerna D; Gius D; Hollingshead MG; Camphausen K; Tofilon PJ
Clin Cancer Res; 2006 May; 12(9):2912-8. PubMed ID: 16675588
[TBL] [Abstract][Full Text] [Related]
9. Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarba-zone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-soluble prodrugs.
Li J; Zheng LM; King I; Doyle TW; Chen SH
Curr Med Chem; 2001 Feb; 8(2):121-33. PubMed ID: 11172670
[TBL] [Abstract][Full Text] [Related]
10. Alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazone inhibitors of ribonucleoside diphosphate reductase.
Booth BA; Agrawal KC; Moore EC; Sartorelli AC
Cancer Res; 1974 Jun; 34(6):1308-14. PubMed ID: 4363653
[No Abstract] [Full Text] [Related]
11. Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors.
Yu Y; Kalinowski DS; Kovacevic Z; Siafakas AR; Jansson PJ; Stefani C; Lovejoy DB; Sharpe PC; Bernhardt PV; Richardson DR
J Med Chem; 2009 Sep; 52(17):5271-94. PubMed ID: 19601577
[No Abstract] [Full Text] [Related]
12. 2-Chloro-2'-deoxyadenosine (2CdA) biochemical aspects of antileukemic efficacy.
Fabianowska-Majewska K; Wyczechowska D
Acta Pol Pharm; 1996; 53(4):231-9. PubMed ID: 9415193
[TBL] [Abstract][Full Text] [Related]
13. Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.
Karp JE; Lancet JE
Cancer Invest; 2007 Sep; 25(6):484-94. PubMed ID: 17882662
[TBL] [Abstract][Full Text] [Related]
14. Ribonucleotide reductase: a critical enzyme for cancer chemotherapy and antiviral agents.
Cerqueira NM; Fernandes PA; Ramos MJ
Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):11-29. PubMed ID: 18221051
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?
Mannargudi MB; Deb S
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1499-1529. PubMed ID: 28624910
[TBL] [Abstract][Full Text] [Related]
17. A new era for ribonucleoside reductase inhibition.
Giles FJ
Leuk Res; 2007 Sep; 31(9):1163-4. PubMed ID: 17416414
[No Abstract] [Full Text] [Related]
18. Clinical trials referral resource. Current clinical trials investigating 3-AP.
Low JA; Schoenfeldt M
Oncology (Williston Park); 2005 Mar; 19(3):354, 357-8. PubMed ID: 15828551
[No Abstract] [Full Text] [Related]
19. 2,2'-Bipyridyl-6-carbothioamide and its ferrous complex: their in vitro antitumoral activity related to the inhibition of ribonucleotide reductase R2 subunit.
Nocentini G; Federici F; Franchetti P; Barzi A
Cancer Res; 1993 Jan; 53(1):19-26. PubMed ID: 8416745
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd).
Zahedi Avval F; Berndt C; Pramanik A; Holmgren A
Biochem Biophys Res Commun; 2009 Feb; 379(3):775-9. PubMed ID: 19121624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
